The gap between pharmaceutical acquisition costs and hospital charges is particularly wide for 340B entities. (Photo: Shutterstock)
Reimbursement for clinician-administered drugs under Medicare Part B is set at the average sales price charged by manufacturers to wholesalers, plus a 6% markup. Although these prices had long been confidential, hospitals now are required to post payer-specific negotiated prices under a transparency rule that took effect early this year.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
